Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A further update on the role of excitotoxicity in the pathogenesis of Parkinson’s disease
Giulia Ambrosi, Silvia Cerri, Fabio Blandini
Journal of Neural Transmission (2013) Vol. 121, Iss. 8, pp. 849-859
Closed Access | Times Cited: 181

Showing 1-25 of 181 citing articles:

Mitophagy of damaged mitochondria occurs locally in distal neuronal axons and requires PINK1 and Parkin
Ghazaleh Ashrafi, Julia S. Schlehe, Matthew J. LaVoie, et al.
The Journal of Cell Biology (2014) Vol. 206, Iss. 5, pp. 655-670
Open Access | Times Cited: 472
The Role of Magnesium in Neurological Disorders
Anna E. Kirkland, Gabrielle L. Sarlo, Kathleen F. Holton
Nutrients (2018) Vol. 10, Iss. 6, pp. 730-730
Open Access | Times Cited: 267
The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseases
Nolwen L. Rey, Daniel W. Wesson, Patrik Brundin
Neurobiology of Disease (2016) Vol. 109, pp. 226-248
Open Access | Times Cited: 230
Central Role of Glutamate Metabolism in the Maintenance of Nitrogen Homeostasis in Normal and Hyperammonemic Brain
Arthur J.L. Cooper, Thomas M. Jeitner
Biomolecules (2016) Vol. 6, Iss. 2, pp. 16-16
Open Access | Times Cited: 196
Calcium Permeable-AMPA Receptors and Excitotoxicity in Neurological Disorders
Changyong Guo, Yao Ying
Frontiers in Neural Circuits (2021) Vol. 15
Open Access | Times Cited: 118
Current approaches to enhance glutamate transporter function and expression
Andréia C. K. Fontana
Journal of Neurochemistry (2015) Vol. 134, Iss. 6, pp. 982-1007
Open Access | Times Cited: 144
Converging roles of ion channels, calcium, metabolic stress, and activity pattern of Substantia nigra dopaminergic neurons in health and Parkinson's disease
Johanna Duda, Christina Pötschke, Birgit Liss
Journal of Neurochemistry (2016) Vol. 139, Iss. S1, pp. 156-178
Open Access | Times Cited: 142
Metabolic Dysfunction in Parkinson’s Disease: Bioenergetics, Redox Homeostasis and Central Carbon Metabolism
Annadurai Anandhan, Maria S. Jacome, Shulei Lei, et al.
Brain Research Bulletin (2017) Vol. 133, pp. 12-30
Open Access | Times Cited: 138
Prokineticin‐2 promotes chemotaxis and alternative A2 reactivity of astrocytes
Matthew Neal, Jie Luo, Dilshan S. Harischandra, et al.
Glia (2018) Vol. 66, Iss. 10, pp. 2137-2157
Open Access | Times Cited: 123
Riboflavin Has Neuroprotective Potential: Focus on Parkinson’s Disease and Migraine
Eyad T. Marashly, Saeed Bohlega
Frontiers in Neurology (2017) Vol. 8
Open Access | Times Cited: 101
Role for VGLUT2 in selective vulnerability of midbrain dopamine neurons
Thomas Steinkellner, Vivien Zell, Zachary J. Farino, et al.
Journal of Clinical Investigation (2018) Vol. 128, Iss. 2, pp. 774-788
Open Access | Times Cited: 90
The Effect of Caffeine on the Risk and Progression of Parkinson’s Disease: A Meta-Analysis
Chien‐Tai Hong, Lung Chan, Chyi‐Huey Bai
Nutrients (2020) Vol. 12, Iss. 6, pp. 1860-1860
Open Access | Times Cited: 90
Calcium-Handling Defects and Neurodegenerative Disease
Sean Schrank, Nikki M. Barrington, Grace E. Stutzmann
Cold Spring Harbor Perspectives in Biology (2019) Vol. 12, Iss. 7, pp. a035212-a035212
Open Access | Times Cited: 89
Regional brain iron and gene expression provide insights into neurodegeneration in Parkinson’s disease
George E. Thomas, Angeliki Zarkali, Mina Ryten, et al.
Brain (2021) Vol. 144, Iss. 6, pp. 1787-1798
Open Access | Times Cited: 79
Anti-inflammatory and Neuroprotective Agents in Clinical Trials for CNS Disease and Injury: Where Do We Go From Here?
Khalil Mallah, Christine Couch, Davis Borucki, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 70
Nuclear factor‐kappa B (NF‐κB) in pathophysiology of Parkinson disease: Diverse patterns and mechanisms contributing to neurodegeneration
Mahsa Dolatshahi, Mohammad Hossein Ranjbar Hameghavandi, Mohammadmahdi Sabahi, et al.
European Journal of Neuroscience (2021) Vol. 54, Iss. 1, pp. 4101-4123
Closed Access | Times Cited: 57
Striatal glutamatergic hyperactivity in Parkinson's disease
Federica Campanelli, Giuseppina Natale, Gioia Marino, et al.
Neurobiology of Disease (2022) Vol. 168, pp. 105697-105697
Closed Access | Times Cited: 45
Glucose metabolism impairment in Parkinson’s disease
Chengcheng Dai, Changhong Tan, Lili Zhao, et al.
Brain Research Bulletin (2023) Vol. 199, pp. 110672-110672
Open Access | Times Cited: 39
Translational molecular imaging and drug development in Parkinson’s disease
Ahmed Haider, Nehal H. Elghazawy, Alyaa Dawoud, et al.
Molecular Neurodegeneration (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 30
Parkinson’s disease-derived α-synuclein assemblies combined with chronic-type inflammatory cues promote a neurotoxic microglial phenotype
Cansu Yildirim-Balatan, Alexis Fenyi, Pierre Besnault, et al.
Journal of Neuroinflammation (2024) Vol. 21, Iss. 1
Open Access | Times Cited: 10
Metabotropic glutamate receptors as therapeutic targets in Parkinson's disease: An update from the last 5 years of research
Nadhir Litim, Marc Morissette, Thérèse Di Paolo
Neuropharmacology (2016) Vol. 115, pp. 166-179
Closed Access | Times Cited: 78
Mitochondrial SIRT3 and neurodegenerative brain disorders
Anamika Anamika, Archita Khanna, Papia Acharjee, et al.
Journal of Chemical Neuroanatomy (2017) Vol. 95, pp. 43-53
Closed Access | Times Cited: 77
GLT-1 transporter: An effective pharmacological target for various neurological disorders
Neha Soni, B.V. Krishna Reddy, Puneet Kumar
Pharmacology Biochemistry and Behavior (2014) Vol. 127, pp. 70-81
Closed Access | Times Cited: 75
The impact of metabotropic glutamate receptors into active neurodegenerative processes: A “dark side” in the development of new symptomatic treatments for neurologic and psychiatric disorders
Valeria Bruno, Filippo Caraci, Agata Copani, et al.
Neuropharmacology (2016) Vol. 115, pp. 180-192
Closed Access | Times Cited: 67
SUMO‐regulated mitochondrial function in Parkinson's disease
Ana Cristina Guerra Souza, Rui Daniel Prediger, Helena Cimarosti
Journal of Neurochemistry (2016) Vol. 137, Iss. 5, pp. 673-686
Open Access | Times Cited: 63
Page 1 - Next Page

Scroll to top